Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sirnaomics Raises $10 Million in Series B Funding Led by Hong Kong Firm

publication date: May 4, 2016
Sirnaomics, a Maryland developer of RNAi therapeutics, closed a $10 million Series B financing, led by Hong Kong-based venture fund, Value Measured Investment Limited. Sirnaomics said the capital will support a US Phase I trial of its lead candidate, STP705, an anti-fibrosis therapeutic. STP705 is expected to start trials in patients with hypertrophied scar tissue in 2H of 2016. In January of this year, Sirnaomics' China partner, Guangzhou Xiangxue Pharma filed to start a similar China trial. More details....

Stock Symbol: (SZE: 300147)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital